You are here

Lucentis

FDA begins review of Samsung Bioepis/Biogen’s Lucentis biosimilar

FDA begins review of Samsung Bioepis/Biogen’s Lucentis biosimilar

Pharmaforum

Samsung Bioepis

Flag link:

Roche, already prepping 2021 launch, charts big expansion plans for Lucentis eye implant

Roche, already prepping 2021 launch, charts big expansion plans for Lucentis eye implant

Fierce Pharma

macular degeneration

wet age-related macular degeneration

Flag link:

Novartis, Roche fined $526M in France for alleged Lucentis marketing missteps

Novartis, Roche fined $526M in France for alleged Lucentis marketing missteps

Fierce Pharma

anti-competitive scheme

Flag link:

'No presents anymore': Inside Novartis' scheme to boost Lucentis sales in Greece

'No presents anymore': Inside Novartis' scheme to boost Lucentis sales in Greece

Fierce Pharma

Flag link:

AsclepiX Emerges With $35M and an Eye Drug Challenger to Eylea, Lucentis

AsclepiX Emerges With $35M and an Eye Drug Challenger to Eylea, Lucentis

Xconomy

AsclepiX Therapeutics

wet age-related macular degeneration

retinal occulsion

Flag link:

Biogen signs marketing deal for two ophthalmology biosimilars

Biogen signs marketing deal for two ophthalmology biosimilars

Pharmaforum

Samsung Bioepis

Flag link:

Does an improved safety profile strengthen Allergan's case for a wet AMD challenge to Lucentis?

Does an improved safety profile strengthen Allergan's case for a wet AMD challenge to Lucentis?

Endpoints

wet age-related macular degeneration

Molecular Partners

Flag link:

Regeneron and Roche Duke it Out in the Diabetic Retinopathy Market

Regeneron and Roche Duke it Out in the Diabetic Retinopathy Market

BioSpace

diabetic retinopathy

Flag link:

Novartis plans to file for new Lucentis indication in ROP

Novartis plans to file for new Lucentis indication in ROP

Pharmaceutical Business Review

retinopathy of prematurity

Flag link:

Roche, Novartis' Italian heads risk trial for alleged market rigging: sources

Roche, Novartis' Italian heads risk trial for alleged market rigging: sources

Yahoo/Reuters

marketing manipulation

Flag link:

Lucentis biosimilar: Formycon eyes 2020 for US launch

Lucentis biosimilar: Formycon eyes 2020 for US launch

BioPharma Reporter

Genentech/Roche

Flag link:

3 Big Pharma Companies With the Best Pipelines

3 Big Pharma Companies With the Best Pipelines

Motley Fool

Flag link:

Biotechs line up to tap growing ophthalmics market

Biotechs line up to tap growing ophthalmics market

BioPharma Dive

Ophthalmic Drugs Market

Ocular Therapeutix

Flag link:

Ophthotech Plunges on Eye Drug Study Failure

Ophthotech Plunges on Eye Drug Study Failure

TheStreet.com

clinical trials

wet age-related macular degeneration

Flag link:

9 Drugs That Cost Medicare a Fortune

9 Drugs That Cost Medicare a Fortune

Motley Fool

Flag link:

Regeneron Eye Drug's Advantage Over Roche's Narrowed in Trial

Regeneron Eye Drug's Advantage Over Roche's Narrowed in Trial

Bloomberg

dry eye disease

Flag link:

Lucentis more effective than lasers for reversing diabetes-induced blindness in new study

Lucentis more effective than lasers for reversing diabetes-induced blindness in new study

BioPharma Dive

proliferative diabetic retinopathy

Flag link:

The Next Blockbusters Could Be Balms For Aging Eyes

The Next Blockbusters Could Be Balms For Aging Eyes

Investors.com

age-related macular degeneration

Applied Genetic Technologies

Avalanche Biotechnologies

Flag link:

Eylea erodes Lucentis, Avastin market share

Eylea erodes Lucentis, Avastin market share

Medical Marketing and Media

Roche/Genentech

Flag link:

Biosimilar of Novartis' eye drug Lucentis launched in India

Biosimilar of Novartis' eye drug Lucentis launched in India

Fierce Pharma

Flag link:

Pages